04 December 2025
04 December 2025
Høeg’s appointment to director of CDER follows a turbulent period for the department, which recently saw the retirement of former head, Richard Padzur.
The decision broadens Jaypirca’s label and converts the December 2023 accelerated approval to a traditional approval status.
The UK government has also pledged to double the portion of GDP that it allocates to innovative drugs, from 0.3% to 0.6%, over the next ten years.
The agreement includes upfront payments, sales and regulatory milestones.
If Padzur retires, he would become one of several high-ranking FDA officials who left the agency in 2025.
New non-primate draft guidance follows the agency’s wider aim to curtail the use of animal testing in preclinical toxicology.
Merging industry-leading business intelligence & award-winning journalism, this is an unrivalled opportunity for engagement with B2B professionals across a network of 40+ leading media websites.
Steer your business strategy with key data and insights from our latest market research reports and company profiles. Not ready to buy? Start small by downloading a sample report first.
Give your business an edge with our leading industry insights.
